Journal
BIOMARKERS IN MEDICINE
Volume 14, Issue 12, Pages -Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/bmm-2020-0331
Keywords
bioinformatics analysis; brain lower grade glioma; RNA sequencing; TCGA; TP53 mutation
Categories
Funding
- Shanghai Municipal Commission of Health and Family Planning Research Project of China [20164Y0170]
- Fundamental Research Funds for the Central Universities [22120180394]
- Tenth People's Hospital of Tongji University of China Climbing Talented Person Plan [04.01.16.025]
- National Natural Science Foundation of China [81901992]
Ask authors/readers for more resources
Aim: Tumor protein p53 (TP53) mutant is one of the most frequently mutated genes in glioma. Results: The Cancer Genome Atlas data has shown that TP53 mutation is present in 49% of lower grade (World Health Organization [WHO] grades II and III) glioma patients. Data from The Genomics of Drug Sensitivity in Cancer database showed that three drugs: (5Z)-7-oxozeaenol, dabrafenib and nutlin-3a (-), have shown more resistance in patients with TP53 mutation. We identified 1100 differentially expressed genes. Functional enrichment analysis showed that the differentially expressed genes are mainly concentrated in the transport of ionic and cancer-related pathways. The top ten hub genes were identified and an outcome analysis revealed the most critical genes related to prognosis. Conclusion: Our results identified the key genes and pathways that might provide the basic proof to improve individualized treatment in patients with glioma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available